Requests that the FDA take the actions set forth below in petition with respect to abbreviated new drug applications (ANDAs) and section 505(b)(2) applications that reference or rely upon OptiNose’s XHANCE® (fluticasone propionate) nasal spray.
🏛 Food and Drug Administration (FDA)FDA-2021-P-0530
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.